Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab

Neal V Palejwala, Andreas K Lauer, Richard G Weleber Oregon Retinal Degeneration Center (ORDC), Ophthalmic Genetics Service and Retina-Vitreous Service, Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA Purpose: To report a rare case of central vision loss in a patient...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Palejwala NV, Lauer AK, Weleber RG
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/82e9caf17e204ae688a59777a241970e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:82e9caf17e204ae688a59777a241970e
record_format	dspace
spelling	oai:doaj.org-article:82e9caf17e204ae688a59777a241970e2021-12-02T02:58:41ZChoroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab1177-5483https://doaj.org/article/82e9caf17e204ae688a59777a241970e2014-09-01T00:00:00Zhttp://www.dovepress.com/choroideremia-associated-with-choroidal-neovascularization-treated-wit-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483 Neal V Palejwala, Andreas K Lauer, Richard G Weleber Oregon Retinal Degeneration Center (ORDC), Ophthalmic Genetics Service and Retina-Vitreous Service, Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA Purpose: To report a rare case of central vision loss in a patient with choroideremia.Patients and methods: A retrospective, interventional case report.Results: A 13-year-old male with history of choroideremia presented with subacute loss of central acuity in his left eye. Examination and diagnostic testing revealed subretinal fibrosis secondary to a choroidal neovascular membrane (CNVM). A trial of anti-vascular endothelial growth factor (VEGF) therapy with the injection of intravitreal bevacizumab was attempted. Mild improvements in acuity and anatomy were noted.Conclusion: Choroideremia is a rare hereditary choroidal dystrophy that predominantly affects males in the first and second decades of life. Visual acuity is usually spared until later in life. CNVM is a rare manifestation of choroideremia with only a handful of case reports presented in the literature. This case is unique in that it is the first reported case that received treatment with intravitreal anti-VEGF therapy. Keywords: anti-VEGF therapy, choroideremia, choroidal neovascular membrane, chorioretinal degeneration, hereditary choroidal dystrophy, intravitreal bevacizumab injectionPalejwala NVLauer AKWeleber RGDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 1675-1679 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Palejwala NV Lauer AK Weleber RG Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab
description	Neal V Palejwala, Andreas K Lauer, Richard G Weleber Oregon Retinal Degeneration Center (ORDC), Ophthalmic Genetics Service and Retina-Vitreous Service, Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA Purpose: To report a rare case of central vision loss in a patient with choroideremia.Patients and methods: A retrospective, interventional case report.Results: A 13-year-old male with history of choroideremia presented with subacute loss of central acuity in his left eye. Examination and diagnostic testing revealed subretinal fibrosis secondary to a choroidal neovascular membrane (CNVM). A trial of anti-vascular endothelial growth factor (VEGF) therapy with the injection of intravitreal bevacizumab was attempted. Mild improvements in acuity and anatomy were noted.Conclusion: Choroideremia is a rare hereditary choroidal dystrophy that predominantly affects males in the first and second decades of life. Visual acuity is usually spared until later in life. CNVM is a rare manifestation of choroideremia with only a handful of case reports presented in the literature. This case is unique in that it is the first reported case that received treatment with intravitreal anti-VEGF therapy. Keywords: anti-VEGF therapy, choroideremia, choroidal neovascular membrane, chorioretinal degeneration, hereditary choroidal dystrophy, intravitreal bevacizumab injection
format	article
author	Palejwala NV Lauer AK Weleber RG
author_facet	Palejwala NV Lauer AK Weleber RG
author_sort	Palejwala NV
title	Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab
title_short	Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab
title_full	Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab
title_fullStr	Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab
title_full_unstemmed	Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab
title_sort	choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/82e9caf17e204ae688a59777a241970e
work_keys_str_mv	AT palejwalanv choroideremiaassociatedwithchoroidalneovascularizationtreatedwithintravitrealbevacizumab AT lauerak choroideremiaassociatedwithchoroidalneovascularizationtreatedwithintravitrealbevacizumab AT weleberrg choroideremiaassociatedwithchoroidalneovascularizationtreatedwithintravitrealbevacizumab
_version_	1718402052700241920

Choroideremia associated with choroidal neovascularization treated with intravitreal bevacizumab

Ejemplares similares